Psychiatric Multi-omics and Neuroimaging Project
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids.
- Who it may be relevant to
- Registry conditions: Mental Disorders, Healthy Control. Basic parameters: 13 years — 35 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Psychiatric Multi-omics and Neuroimaging Project Database
Overview
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
Detailed description
The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.
Interventions
- Drug Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Primary outcome measures
- cortical morphology [Time frame: 40 minutes]
- target gene charaacteristics [Time frame: 1 day]
- scale scores [Time frame: 90 minutes.]
Eligibility criteria
Inclusion criteria
- Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
- Course of disease: <24 months
- Priority is given to patients who have never taken medicine or duration of drug use < 2 weeks
- No nuclear magnetic contraindications.
Exclusion criteria
- Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
- Have a major physical disease or infectious disease
- History of coma and serious neurological disease 4.MRI contraindications.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The Second Xiangya hospital of central south univerity — Changsha
Identifiers
NCT: NCT06580860 · NSFC82201664